Previous 10 | Next 10 |
BeiGene (NASDAQ:BGNE) and Novartis' (NVS) tislelizumab was approved by China's National Medical Products Administration (NMPA) to treat patients with locally advanced or metastatic esophageal squamous cell carcinoma (ESCC) who have disease progression or are intolerant to first-line stan...
VectorBuilder announced plans to build a $500 million gene delivery manufacturing and research campus in Guangzhou. Bayer announced China approval of Vitrakvi™ (larotrectinib), a precision medicine for adult and pediatric patients who have advanced solid tumors that harbor a Ne...
Tislelizumab is now approved for eight indications in China BeiGene, Ltd . (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for pati...
Beigene's (NASDAQ:BGNE) Brukinsa (zanubrutinib) demonstrated superiority over Imbruvica (imbrutinib) based on overall response rate in a phase 3 trial in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The results were also evalua...
BeiGene has switched auditors for its New York listing to a U.S. company from a Chinese one in a move to comply with U.S. law. The change could reduce the company’s threat of being forcibly delisted from Nasdaq. The company looks like quite a safe long-term investment due t...
Final Response Analysis from Global Phase 3 ALPINE Trial Provides Additional Support for Potential Use of BRUKINSA in Relapsed or Refractory CLL/SLL BRUKINSA Safety Results Consistent with ALPINE Interim Analysis BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688...
Results from subanalyses of RATIONALE-303 and -304 add to the growing body of data on tislelizumab as a potential treatment for non-small cell lung cancer Biomarker studies shed light on patient characteristics driving improved response to PD-(L)1 inhibitors BeiGene ...
The European Medicines Agency accepted to review Novartis (NYSE:NVS) and BeiGene's (NASDAQ:BGNE) tislelizumab for patients with advanced or metastatic esophageal squamous cell carcinoma (ESCC) after prior systemic chemotherapy. The marketing authorization applications (MAA) submitted by ...
First European Submissions for BeiGene’s Anti PD-1 antibody Licensed to Novartis for North America, Europe and Japan BeiGene, Ltd . (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and afford...
Tencent reported a lackluster FQ4 earnings card. However, management offered cautiously optimistic guidance from H2'22. Notably, we think it represented a clear departure from the uncertainty in its previous earnings commentary. As such, we encourage Tencent investors to add expos...
News, Short Squeeze, Breakout and More Instantly...
$800 million investment in New Jersey supports global growth and expansion with technologically advanced manufacturing capacity and clinical development capabilities for novel cancer medicines BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today ann...
2024-07-20 02:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
BeiGene , Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced the appointment of Aaron Rosenberg as Chief Financial Officer, effective July 22. Mr. Rosenberg will succeed Julia Wang, who is departing to pursue external opportunities and will stay with the C...